ESPERION THERAPEUTICS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Future earnings · next 8 quarters
| Report date | Fiscal Q | Est. Revenue | Est. EPS | Call Time | In |
|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | $88M | -$0.03 | — | in 7d |
| 2026-08-03 | Q2 2026 | $96M | -$0.00 | — | in 95d |
Forward dates from Finnhub. Smaller filers and foreign listings sometimes publish dates only ~6 weeks before the report — check back closer to the next anticipated quarter.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
ESPR Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyESPR Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics